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1.1. Primary sites: ovarian, fallopian tube, and peritoneal cancer
In 2014, the Gynecologic Oncology Committee of FIGO revised the
staging to incorporate ovarian, fallopian tube, and peritoneal cancer in
the same system. Changing the staging system required extensive
international consultation. The primary site (i.e. ovary, fallopian tube,
or peritoneum) is designated, where possible. When it is not possible
to clearly delineate the primary site, these should be listed as “undesig-
nated” [1,2].
It has been presumed that fallopian tubemalignancies were rare [2].
However, histologic, molecular, and genetic evidence shows that from
40%− 60% of tumors that were classiﬁed as high-grade serous carcino-
mas of the ovary or peritoneummay have originated in the ﬁmbrial end
of the fallopian tube [3–8]. Therefore, the incidence of fallopian tube
cancers may have been substantially underestimated. These new data
support the view that high-grade serous ovarian, fallopian tube, and
peritoneal cancers should be considered collectively, and that the con-
vention of designating malignancies as having an ovarian origin should
no longer be used, unless that is clearly the origination site. It has been
suggested that extrauterine tumors of serous histology arising in the
ovary, fallopian tube, or peritoneummight be described collectively as
“Müllerian carcinomas” [1,2] or “pelvic serous carcinomas” [9]. The lat-
ter tumor designation is controversial because some peritoneal tumors
might arise in extrapelvic peritoneum. Therefore, the simple term “se-
rous carcinoma" is preferred, and most of these are high-grade serous
carcinomas (HGSC).
Although there has been no formal staging for peritoneal cancers,
the FIGO staging system is used with the understanding that it is not
possible to have a Stage I peritoneal cancer.
1.1.1. Primary site
Ovarian epithelial tumorsmay arisewithin endometriosis or cortical
inclusions of Müllerian epithelium, likely a form of endosalpingiosis.
These include low-grade endometrioid carcinomas, clear cell carcino-
mas, borderline and low-grade serous carcinomas, and mucinous carci-
nomas. These tumors are thought to evolve slowly from lower-grade
precursor conditions (endometriotic cysts, cystadenomas, etc.) and are
classiﬁed as type I tumors [5]. Fallopian tube carcinomas arise in the
distal fallopian tube and the majority of these are high-grade serous
carcinomas. These are thought to evolve rapidly from more obscurehttp://dx.doi.org/10.1016/j.ijgo.2015.06.007
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).precursors and are designated as type II tumors [5,6]. This latter group
encompasses high-grade endometrioid carcinomas and carcinosar-
comas. All of these high-grade carcinomas are nearly always associated
with mutations in the TP53 gene [5].
1.1.2. Lymphatic and lymph node drainage
The lymphatic drainage of the ovaries and fallopian tubes is via the
utero-ovarian, infundibulopelvic, and round ligament pathways and
an external iliac accessory route into the following regional lymph
nodes: external iliac, common iliac, hypogastric, lateral sacral, para-
aortic lymph nodes and, occasionally, to the inguinal nodes [1,10–12].
The peritoneal surfaces can drain through thediaphragmatic lymphatics
and thence to the major venous vessels above the diaphragm.
1.1.3. Other metastatic sites
The peritoneum, including the omentum and pelvic and abdominal
viscera, is the most common site for dissemination of ovarian and
fallopian tube cancers. This includes the diaphragmatic and liver
surfaces. Pleural involvement is also seen. Other extraperitoneal or
extrapleural sites are relatively uncommon, but can occur [1,10–12].
After systematic pathologic analysis has excluded a tubal or ovarian
site of origin, malignancies that appear to arise primarily on the perito-
neum have an identical spread pattern, and frequently may involve the
ovaries and fallopian tubes secondarily. These “peritoneal” tumors are
thought to arise in endosalpingiosis.
1.2. Classiﬁcation rules
Although CT scans can delineate the intra-abdominal spread of
disease to a certain extent, ovarian, fallopian tube, and peritoneal can-
cers should be staged surgically. Operative ﬁndings determine the pre-
cise histologic diagnosis, stage, and therefore the prognosis, of the
patient [1,9,10,12–14].
In selected patients with advanced-stage disease, it may be appropri-
ate to initiate chemotherapy prior to surgical intervention, and in these
cases, there should be histological or cytological conﬁrmation of the diag-
nosis prior to starting neoadjuvant chemotherapy (see 5.2.2. below).
Chest radiograms may serve as a screen for pleural effusions. As
distant metastases are infrequent, there is no requirement for other ra-
diological evaluation unless symptomatic. Serum CA125 levels may be
useful in determining response to chemotherapy, but they do not con-
tribute to staging.Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Table 1
FIGO staging classiﬁcation for cancer of the ovary, fallopian tube, and peritoneum.
Stage I: Tumor conﬁned to ovaries or fallopian tube(s)
T1-N0-M0
IA: Tumor limited to 1 ovary (capsule intact) or fallopian tube; no tumor on
ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal
washings
T1a-N0-M0
IB: Tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on
ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal
washings
T1b-N0-M0
IC: Tumor limited to 1 or both ovaries or fallopian tubes, with any of the following:
IC1: Surgical spill
T1c1-N0-M0
IC2: Capsule ruptured before surgery or tumor on ovarian or fallopian tube
surface
T1c2-N0-M0
IC3: Malignant cells in the ascites or peritoneal washings
T1c3-N0-M0
Stage II: Tumor involves 1 or both ovaries or fallopian tubes with pelvic
extension (below pelvic brim) or peritoneal cancer
T2-N0-M0
IIA: Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
T2a-N0-M0
IIB: Extension to other pelvic intraperitoneal tissues
T2b-N0-M0
Stage III: Tumor involves 1 or both ovaries or fallopian tubes, or peritoneal
cancer, with cytologically or histologically conﬁrmed spread to the
peritoneum outside the pelvis and/or metastasis to the retroperitoneal
lymph nodes
T1/T2-N1-M0
IIIA1: Positive retroperitoneal lymph nodes only (cytologically or histologically
proven):
IIIA1(i) Metastasis up to 10 mm in greatest dimension
IIIA1(ii) Metastasis more than 10 mm in greatest dimension
IIIA2: Microscopic extrapelvic (above the pelvic brim) peritoneal involvement
with or without positive retroperitoneal lymph nodes
T3a2-N0/N1-M0
IIIB: Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest
dimension, with or without metastasis to the retroperitoneal lymph nodes
T3b-N0/N1-M0
IIIC: Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in
greatest dimension, with or without metastasis to the retroperitoneal lymph
nodes (includes extension of tumor to capsule of liver and spleen without
parenchymal involvement of either organ)
T3c-N0/N1-M0
Stage IV: Distant metastasis excluding peritoneal metastases
Stage IVA: Pleural effusion with positive cytology
Stage IVB: Parenchymal metastases and metastases to extra-abdominal organs
(including inguinal lymph nodes and lymph nodes outside of the abdominal
cavity)
Any T, any N, M1
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Fallopian tube involvement can be divided into three categories. In
the ﬁrst, an obvious intraluminal and grossly apparent fallopian tube
mass is seen with tubal intraepithelial carcinoma (carcinoma in situ)
that is presumed to have arisen in the fallopian tube. These cases should
be staged surgically with a histological conﬁrmation of disease. Tumor
extension into the submucosa or muscularis and to and beyond the
serosa can therefore be deﬁned. These features, together with the
laterality and the presence or absence of ascites, should all be taken
into consideration [1,3,6,7].
In the second scenario, a widespread serous carcinoma is associated
with a tubal intraepithelial carcinoma. A visiblemass in the endosalpinx
may not be seen but the histologic ﬁndings should be noted in the pa-
thology report since theymay indicate a fallopian tube primary. Tumors
obliterating both fallopian tube and ovary may belong to this group but
whether a presumptive assignment of a tubal origin can be made in
such cases is controversial given that tubal intraepithelial carcinoma
cannot be conﬁrmed.
In the third scenario—the risk-reducing salpingo-oophorectomy—
tubal intraepithelial carcinomamay be the only ﬁnding. It should be re-
ported as originating in the fallopian tube and managed accordingly.
The majority of early serous cancers detected are found in the fallopian
tube, irrespective of genetic risk [15,16].
1.2.2. FIGO staging
The updated, revised FIGO staging system combines the classi-
ﬁcation for ovarian, fallopian tube, and peritoneum cancer. It is based
on ﬁndings made mainly through surgical exploration (as outlined
above). Table 1 presents the 2014 FIGO staging classiﬁcation for cancer
of the ovary, fallopian tube, and peritoneum. The equivalents within the
Union for International Cancer Control (UICC) TNM classiﬁcation are
presented in Table 2.
In addition to these changes, several other modiﬁcations of the
former staging system have been made to better prospectively capture
the data. Stage IC is now divided into three categories, IC1 (surgical
spill), IC2 (capsule ruptured before surgery or tumor on ovarian or
fallopian tube surface), and IC3 (malignant cells in the ascites or perito-
neal washings). Stage IIC has been eliminated. The updated staging
includes a revision of the Stage IIIC based on spread to the retroperito-
neal lymph nodes alonewithout intraperitoneal dissemination, because
an analysis of these patients indicates that their survival is signiﬁcantly
better than thosewhohave intraperitoneal dissemination [17]. This cat-
egory is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest
dimension), and IIIA1(ii) (metastasis N10 mm in greatest dimension).
Stage IIIA2 is now “microscopic extrapelvic peritoneal involvement
with or without positive retroperitoneal lymph node” metastasis. The
wording of Stage IIIB has been modiﬁed to reﬂect the lymph node sta-
tus. Stage IVB now includes metastases to the inguinal lymph nodes.
1.2.2.1. Regional lymph nodes (N)
• NX: Regional lymph nodes cannot be assessed.
• N0: No regional lymph node metastasis.
• N1: Regional lymph node metastasis.
1.2.2.2. Distant metastasis (M)
• MX: Distant metastasis cannot be assessed.
• M0: No distant metastasis.
• M1: Distant metastasis (excluding peritoneal metastasis).
1.3. Histopathologic classiﬁcation
The majority of cases of ovarian cancer are of epithelial origin. FIGO
endorses the WHO histological typing of epithelial ovarian tumors. It isrecommended that all ovarian epithelial tumors be subdivided accord-
ing to the classiﬁcation given below [18].
The histologic classiﬁcation of ovarian, fallopian tube, and peritoneal
neoplasia is as follows:
• Serous tumors.
• Mucinous tumors.
• Endometrioid tumors.
• Clear cell tumors.
• Brenner tumors.
• Undifferentiated carcinomas (this group of malignant tumors is of ep-
ithelial structure, but they are too poorly differentiated to be placed in
any other group).
• Mixed epithelial tumors (these tumors are composed of two or more
of the ﬁvemajor cell types of common epithelial tumors. The types are
usually speciﬁed).
• Cases with high-grade serous carcinoma in which the ovaries and
fallopian tubes appear to be incidentally involved and not the primary
origin can be labeled as peritoneal carcinoma or serous carcinoma of
undesignated site, at the discretion of the pathologist.
Table 2
Cancer of the ovary, fallopian tube and peritoneum: FIGO staging (2014) compared with
TNM classiﬁcation.a
FIGO UICC
(Designate primary: Tov, Tft, Tp, or Tx) T N M
Stage
IA T1a N0 M0
IB T1b N0 M0
IC T1c N0 M0
IIA T2a N0 M0
IIB T2b N0 M0
IIIA T3a N0 M0
T3a N1 M0
IIIB T3b N0 M0
T3b N1 M0
IIIC T3c N0−1 M0
T3c N1 M0
IV Any T Any N M1
Regional nodes (N)
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis (M)
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis (excluding peritoneal
metastasis)
Notes:
1. The primary site—that is, ovary, fallopian tube, or peritoneum—should be designated
where possible. In some cases, it may not be possible to clearly delineate the primary
site, and these should be listed as “undesignated.”
2. The histologic type should be recorded.
3. The staging includes a revision of the Stage III patients and allotment to Stage IIIA1 is
based on spread to the retroperitoneal lymph nodes without intraperitoneal dissemina-
tion, because an analysis of these patients indicates that their survival is signiﬁcantly
better than those who have intraperitoneal dissemination.
4. Involvement of retroperitoneal lymphnodesmust beproven cytologically or histologically.
5. Extension of tumor fromomentumto spleenor liver (Stage IIIC) shouldbedifferentiated
from isolated parenchymal splenic or liver metastases (Stage IVB).
a Reproduced with permission from Berek et al. [1], p.482.
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subclassiﬁed by histologic grading, which can be correlated with prog-
nosis. This grading system does not apply to nonepithelial tumors
[19]. Two grading systems are applied. For non-serous carcinomas
(most endometrioid and mucinous), grading is identical to that used
in the uterus, based on architecture with a one-step upgrade if there is
prominent nuclear atypia, as follows:
• GX: Grade cannot be assessed.
• G1: Well differentiated.
• G2: Moderately differentiated.
• G3: Poorly differentiated.
Serous carcinomas are the most common in both the ovary and
tube. More than 90% of fallopian tube carcinomas are serous or high-
grade endometrioid adenocarcinoma. Other cell types have been
reported, but are rare [1,2,24]. Serous carcinomas are graded in a two-
grade system beﬁtting their biology. High-grade serous carcinomas,
including both classic-appearing and those with SET features (solid,
endometrioid-like, and transitional) carry a high frequency of muta-
tions in TP53 [20–22]. Low-grade serous carcinomas are often associated
with borderline or atypical proliferative serous tumors, often contain
mutations in BRAF andKRAS and containwild-type TPp53. Most “moder-
ately differentiated” serous carcinomas carry mutations in TP53 and
should be combined with the high-grade tumors [19,21–23].
Nonepithelial cancers, although uncommon, are extremely im-
portant. These include granulosa cell tumors, germ cell tumors, sarco-
mas, and lymphomas. They are discussed below as separate entities.Metastatic neoplasms to the ovary, such as tumors arising in the lower
reproductive tract sites (cervix or uterine carcinomas) and gastroin-
testinal tract (signet ring cell [Krukenberg] carcinomas, low grade
appendiceal or pancreaticobiliary mucinous tumors and other neo-
plasms) are graded and staged in accordance with their respective
sites of origin [1,2].
2. Epidemiology
Malignant tumors of the ovaries occur at all ages with variation in
histological subtype by age. For example, in women younger than
20 years of age, germ cell tumors predominate, while borderline tumors
typically occur in women in their 30s and 40s—10 or more years youn-
ger than in women with invasive epithelial ovarian cancers, which
mostly occur after the age of 50 years.
The lifetime risk of awoman in the USA developing ovarian cancer is
approximately 1 in 70. Approximately 23% of gynecologic cancers are
ovarian in origin, but 47% of all deaths from cancer of the female genital
tract occur in women with ovarian cancer. Overall, epithelial ovarian
cancer accounts for 4% of all new cancer diagnoses in women and 5%
of all cancer-related deaths [1,2,25].
The overall incidence of epithelial tumors varies from 9–17 per
100 000 and is highest in industrialized countries, with the exception
of Japan [26]. However, this incidence rate increases proportionately
with age. The largest number of patients with epithelial ovarian cancer
is found in the 60–64 years age group.
Established risk factors for epithelial ovarian tumors include repro-
ductive risk factors. Women who have never had children are twice as
likely to develop this disease. First pregnancy at an early age, earlymen-
opause, and the use of oral contraceptives have been associated with
lower risks of ovarian cancer [27]. The relationship of these variables
to fallopian tube cancer is unclear.
As noted above, it has been previously presumed that fallopian tube
malignancies were rare; however, this has been challenged by evidence
to show that many tumors that were classiﬁed as serous carcinomas of
the ovary or peritoneal cancers appear to have their origin in the
fallopian tube [3–7]. When the origin is uncertain, the convention of
designating all serous cancers, as originating in the ovary should no lon-
ger be used and the term “undesignated origin” may be applied at the
discretion of the pathologist [18].
2.1. Genetics
Hereditary factors are implicated in approximately 10% of ovarian,
fallopian tube, and peritoneal cancers. Mutations that have been identi-
ﬁed include [28–32]:
(1) Inherited pathologenic mutations in the BRCA1 and the BRCA2
genes. Women who carry germline mutations in BRCA1 and
BRCA2 have a substantially increased risk of ovarian, tubal, and
peritoneal cancer—about 20%–50% with BRCA1 and 10%–20%
with BRCA2 [29–32]. Typically these cancers occur at an earlier
age than sporadic cancers, particularly in BRCA1 mutation car-
riers, with a median age of diagnosis in the mid-40s.
(2) Inherited mutations in the mismatch repair genes associated
with Type II Lynch Syndrome. Women carrying these mutations
have an increased risk of a number of cancers including colon,
endometrial, and ovarian cancer. Typically, the ovarian cancers
that occur are endometrioid or clear cell histologically and are
usually Stage I.
(3) Inherited mutation in ARID1 is associated with clear cell and
endometrioid carcinomas [33].
Patients with a strong family history of epithelial ovarian, fallo-
pian tube, or peritoneal cancers, particularly if there is a documented
germline mutation, are advised to have a risk-reducing bilateral
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pletion of childbearing. All women who are suspected of carrying a
BRCA germline mutation, based on family history or young age of diag-
nosis and a high-grade serous or high-grade endometrioid cancer,
should be offered genetic testing. BRCA mutations may also occur in
women without a family history of breast/ovarian cancer, and genetic
testing should be considered in patients from ethnic groups where
there is a high incidence of founder mutations (e.g. Ashkenazi Jewish
ancestry), and in women with high-grade serous cancers under the
age of 70 years [26–30]. Australian guidelines [34] suggest that all
women with epithelial ovarian cancer diagnosed under the age of 70
should be considered for BRCA mutation testing independent of family
history and histological subtype. In contrast, the Society of Gynecologic
Oncology (SGO) recommends that all women diagnosed with ovarian,
fallopian tube, or peritoneal carcinoma, regardless of age or family his-
tory, should receive genetic counseling and be offered genetic testing
[35]. Women whose family history suggests Lynch II syndrome should
undergo appropriate genetic counseling and testing.
3. Screening
To date, there are no documented effective screening methods that
reduce the mortality of ovarian, fallopian tube, or peritoneal cancers.
Studies using CA125, ultrasonography of the pelvis, and pelvic examina-
tion do not have an acceptable level of sensitivity and speciﬁcity, but tri-
als are in progress in women in the general population and those in the
high-risk population. Women at increased genetic risk should be en-
couraged to consider risk-reducing bilateral salpingo-oophorectomy,
as this is the most effective way to reduce mortality in this population
of women [36,37]. An ACOG bulletin has recommended that opportu-
nistic (at the time of a clinically indicated hysterectomy) bilateral
salpingectomy be considered in women not at genetic risk who wish
to retain their ovaries as a way to reduce their risk of later developing
high-grade serous carcinomas [38].
4. Diagnosis
Patients with epithelial ovarian cancers conﬁned to the ovary or
fallopian tube at initial diagnosis have a very good prognosis [39–42].
The symptoms are often very insidious and the duration of symptoms
not very different between patients with early stage or advanced stage
disease [13,14]. This may reﬂect the different biological behavior of
the various histological subtypes; for example, grade 1 serous, clear
cell, mucinous, and endometrioid cancers are commonly early stage at
presentation, whereas high-grade serous cancers are most often Stage
III because of early dissemination by a more aggressive cancer. Tumor
markers such as human gonadotropin (hCG) and alpha-fetoprotein
(AFP) are mandatory to exclude germ cell tumors in younger patients
with a pelvic mass or suspicious enlargement of an ovary.
Approximately two-thirds of all epithelial “ovarian” cancers are
Stage III or Stage IV at diagnosis. Presenting symptoms include vague
abdominal pain or discomfort, menstrual irregularities, and dyspepsia
and other mild digestive disturbances, which may have been present
for only a few weeks [13,14,43]. As the disease progresses, abdominal
distention and discomfort from ascites generally worsen, and may be
associated with respiratory symptoms from increased intra-abdominal
pressure or from the transudation of ﬂuid into the pleural cavities. Ab-
normal vaginal bleeding is an uncommon symptom.
Fallopian tube and peritoneal cancers likely present the same as
ovarian cancer. Past analyses have been biased because many fallopian
tube cancers have been presumed to arise in the ovaries.
A detailed medical history must be taken to ascertain possible risk
factors, history of other cancers, and history of cancer in the family.
Then a complete physical examination, including general, breast, pelvic,
and rectal examination, must be performed [1].Prior to surgery a chest radiograph should be taken to screen for a
pleural effusion and a CT scan of the abdomen and pelvis should be per-
formed to delineate the extent of intra-abdominal disease. However, in
the absence of extra-abdominopelvic disease, radiological scanning
does not replace surgical staging with laparotomy. Tumor markers in-
cluding CA125, and carcinoembryonic antigen (CEA) should be consid-
ered [1].With a high CA125 level, themost common diagnosis would be
epithelial ovarian, fallopian tube, or peritoneal cancer.
A gastric or colonic primary with metastases to the ovaries may
mimic ovarian cancer, and if the CEA is elevated, this should be con-
sidered. A current mammogram should be considered as patients are
frequently in the age groupwhere breast cancer is prevalent. A colonos-
copy is indicated when symptoms suggest possible bowel cancer [1].
The following factors point to the presence of a malignancy, and are
useful in the clinical assessment of masses:
• Age of the patient (young for germ cell, older for epithelial
malignancies).
• Bilaterality.
• Tumor ﬁxation clinically.
• Ascites.
• Ultrasonographically complex, especially if solid areas.
• CT ﬁnding of metastatic nodules.
• Elevated tumor markers.
5. Primary surgery
In general, the prognosis of epithelial ovarian, fallopian, and perito-
neal malignancies is independently affected by the following [1,44,45]:
• Stage of the cancer at diagnosis.
• Histological type and grade.
• Maximum diameter of residual disease after cytoreductive surgery.
5.1. Staging laparotomy
A thorough staging laparotomy is an important part of early
management. If the preoperative suspicion is malignancy, a lapa-
rotomy should be performed. If there is no visible or palpable evidence
of metastasis, the following should be performed for adequate staging
[1,10,11,13,14]:
• Careful evaluation of all peritoneal surfaces.
• Retrieval of any peritonealﬂuid or ascites. If there is none, washings of
the peritoneal cavity should be performed.
• Infracolic omentectomy.
• Selective lymphadenectomy of the pelvic and para-aortic lymph
nodes, at least ipsilateral if the malignancy is unilateral.
• Biopsy or resection of any suspicious lesions, masses, or adhesions.
• Random peritoneal biopsies of normal surfaces, including from the
undersurface of the right hemidiaphragm, bladder reﬂection, cul-de-
sac, right and left paracolic recesses, and both pelvic sidewalls.
• Total abdominal hysterectomy and bilateral salpingo-oophorectomy
in most cases.
• Appendectomy for mucinous tumors.
Upon entering the abdominopelvic cavity, the peritoneal ﬂuid
should be sent for cytology. In the absence of ascites, irrigation should
be performed and washings sent for cytology.
The laparotomy should proceed with a detailed examination of the
contents, including all the peritoneal surfaces. In addition to all the sus-
picious sites, biopsies from the peritoneal reﬂection of the bladder, the
posterior cul-de-sac, both paracolic gutters, subdiaphragmatic surfaces,
and both pelvic sidewalls should be taken. The primary tumor, if limited
to the ovary, should be examined to look for capsular rupture. All
S115J.S. Berek et al. / International Journal of Gynecology and Obstetrics 131 (2015) S111–S122obvious sites of tumor must be removed wherever possible in addition
to total hysterectomy and bilateral salpingo-oophorectomy. The omen-
tum, pelvic, and para-aortic lymph nodes should be removed for histo-
logical examination.
In younger women, fertility may be an issue. In these patients, con-
servative surgery, with preservation of the uterus and contralateral
ovary, should be considered after informed consent [40].
Clinical judgment is important in the approach to a pelvic mass in
the young, reproductive-aged woman. If the suspicion is strong for
malignancy, open laparotomy is generally indicated. Laparoscopy may
be more appropriate if the suspicion is more for benign disease, where
tumor markers (including hCG and AFP) are normal. A biopsy of any
suspicious lesion can be performed and frozen section obtained in
order to proceed expeditiously with deﬁnitive surgery.
Ovaries and fallopian tubes should be evaluated as thoroughly as
possible to establish the site of origin. If visible, the entire tube, particu-
larly the distal portion, should be submitted for pathology and exam-
ined using the SEE-FIM protocol [32]. Ovaries should be scrutinized for
coexisting endometriotic cysts, adenoﬁbromas, or other benign condi-
tions that could serve as a nidus of tumor development.
5.2. Cytoreductive (debulking) surgery for advanced stage disease
5.2.1. Primary debulking
At least two-thirds of patients with ovarian cancer present with
Stage III or IV disease. Thismay affect the performance status andﬁtness
for surgery. However, the most important prognostic indicator in
patients with advanced stage ovarian cancer is the volume of residual
disease after surgical debulking. Therefore, patients whose medical
condition permits should generally undergo a primary laparotomy
with total abdominal hysterectomy, bilateral salpingo-oophorectomy,
omentectomy, and maximal attempt at optimal cytoreduction [1,
44–46]. This may necessitate bowel resection, and occasionally, partial
or complete resection of other organs. Systematic pelvic and para-
aortic lymphadenectomy of non-enlarged nodes does not improve
overall survival, when compared with removal of bulky nodes only,
although there is a modest improvement in progression-free survival
[47]. Level of Evidence A
5.2.2. Interval debulking
In selected patients with cytologically proven Stage IIIC and IV
disease who may not be good surgical candidates, 2–3 cycles of neoad-
juvant chemotherapy may be given initially, followed by interval surgi-
cal cytoreduction and additional chemotherapy [48]. This is particularly
useful in patientswith a large pleural effusion and/or gross ascites. In se-
lected patients whose primary cytoreduction is considered suboptimal,
particularly if a gynecologic oncologist did not perform the initial oper-
ation, interval debulkingmay be considered after 2–3 cycles of systemic
chemotherapy [1,48,49]. Pathologic assessment for residual tumor fol-
lowing neoadjuvant therapy will enable an estimate of residual disease,
with modest predictive value in terms of survival [50].
6. Chemotherapy
6.1. Chemotherapy for early stage cancer
The prognosis of patients with adequately staged tumors with Stage
IA and Stage IB grade 1–2 epithelial cancers of the ovary is very good;
adjuvant chemotherapy does not provide additional beneﬁts and is
not indicated. For higher-grade tumors and for patients with Stage IC
disease, adjuvant platinum-based chemotherapy is given to most pa-
tients, although there has been debate about the absolute survival ben-
eﬁt in women with Stage IA and IB cancers who have had thorough
surgical staging [39]. All patients with Stage II disease should receive
adjuvant chemotherapy. The optimal number of cycles in patients
with Stage I disease has not been deﬁnitively established, but typicallybetween 3 and 6 cycles are administered. The Gynecologic Oncology
Group (GOG) 157 study suggested that 3 cycles of carboplatin and
paclitaxel was equivalent to 6 cycles, but in subgroup analysis, 6 cycles
appeared superior in patients with high-grade serous cancers [46].
There is no evidence to support adjuvant therapy for carcinoma in
situ of the fallopian tube and it is not recommended [1,2,41]. Level of
Evidence A
6.2. Chemotherapy for advanced stage ovarian cancer
Patients who have had primary cytoreduction should receive che-
motherapy following surgery [1,51] (Table 3). The accepted standard
is 6 cycles of platinum-based combination chemotherapy, with a plati-
num (carboplatin or cisplatin) and a taxane (paclitaxel or docetaxel)
[52–56]. Docetaxel may be considered in selected patients as it has
less neurotoxicity, but it is more myelosuppressive than paclitaxel
[52]. One relatively small study reported that maintenance chemother-
apy with monthly paclitaxel increased disease-free interval but not
overall survival [57]. The role of maintenance chemotherapy is uncer-
tain, is not standard practice, and is being investigated in clinical trials.
Although intraperitoneal chemotherapy has been shown to be
associated with improved progression-free survival and overall survival
in selected patients with optimally debulked Stage III ovarian cancer, it
is not widely used outside the USA because of concerns regarding in-
creased toxicity and catheter-related problems, and the beneﬁts are
still debated [58–62]. The GOG172 trial compared intravenous paclitax-
el plus cisplatin with intravenous paclitaxel plus intraperitoneal
cisplatin and paclitaxel in patients with Stage III ovarian or peritoneal
carcinoma, with no residual disease greater than 1 cm in diameter
[60]. Only 42% of patients in the intraperitoneal group completed
6 cycles of the assigned therapy, but the intraperitoneal group had
an improvement in progression-free survival of 5.5 months (23.8 vs
18.3 months; P = 0.05) and an improvement in overall survival of
15.9 months (65.6 vs 49.7 months; P= 0.03). Further studies of intra-
peritoneal therapy are ongoing. Level of Evidence A
Combination chemotherapywith either intravenous carboplatin and
paclitaxel or intraperitoneal cisplatin and paclitaxel (using the GOG 172
protocol) are the standard treatment options for patientswith advanced
disease, with evidence to support the addition of bevacizumab in select-
ed patients. The advantages and disadvantages of the intravenous ver-
sus intraperitoneal routes of administration of these drugs should be
discussed with the patient. Intraperitoneal chemotherapy is applicable
only to patientswith advanceddiseasewhohave had optimal debulking
and have less than 1 cm residual disease. It should be used only in cen-
ters that have experience with intraperitoneal chemotherapy.
The recommended doses and schedule for intravenous chemo-
therapy are: carboplatin (starting dose AUC 5–6), and paclitaxel
(175 mg/m2), every 3 weeks for 6 cycles [47], or the dose-dense regi-
men of carboplatin AUC 6 every 3 weeks for 6 cycles and weekly pacli-
taxel 80 mg/m2 [62]. The Japanese GOG (JGOG) reported the ﬁndings of
the latter regimen and showed improved progression-free survival and
overall survival [63]. This regimen is being compared with standard
every 3 weeks intravenous and intraperitoneal regimens in several
clinical trials. An Italian trial (MITO-7) investigated a different schedule
of weekly carboplatin (AUC 2 mg/mL per min) plus weekly paclitaxel
(60mg/m2) comparedwith carboplatin (AUC 6mg/mL permin, admin-
istered every 3 weeks) and paclitaxel (175 mg/m2) [64]. The weekly
regimen did not signiﬁcantly improve progression-free survival com-
pared with the conventional regimen (18.8 months vs 16.5 months;
P = 0.18), but was associated with better quality of life and fewer
toxic effects. Other ongoing studies, including the ICON 8 trial and the
GOG 262 trial are assessing dose-dense chemotherapy, and will help
answer the important question regarding the role of dose − dense
chemotherapy in a white population.
The recommended doses and schedule for intraperitoneal chemo-
therapy are paclitaxel 135 mg/m2 intravenously on day one, followed
Table 3
Chemotherapy for advanced epithelial ovarian cancer: recommended regimens.a
Drugs
Standard regimens
Dose Administration (h) Interval No. of treatments
Carboplatin AUC = 5–6 3 Every 3 weeks 6–8 cycles
Paclitaxel 175 mg/m2
Carboplatin AUC = 5-6 3 Every 3 weeks 6 cycles
Paclitaxel 80 mg/m2 Every week 18 weeks
Carboplatin AUC = 5 3 Every week 6 cycles
Docetaxel 75 mg/m2 Every 3 weeks
Cisplatin 75 mg/m2 3 Every 3 weeks 6 cycles
Paclitaxel 135 mg/m2
Carboplatin (single agent) b AUC = 5 3 Every 3 weeks 6 cycles, as tolerated
AUC, area under the curve dose by Calvert formula (287).
Abbreviation: AUC, area under the curve dose by the methods of Calvert et al. [65] and Nagao et al. [66].
a Reproduced with permission from Berek et al. [1], p.510.
b In patients who are elderly, frail, or poor performance status.
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paclitaxel 60 mg/m2 intraperitoneally on day eight, every 3 weeks for
6 cycles, as tolerated [58–60]. Many centers modify the dose of cisplatin
to 75mg/m2 rather than 100mg/m2 thatwas used inGOG172 to reduce
toxicity. Others substitute carboplatin (AUC 5–6) for cisplatin in the
regimen. The impact on outcome of these pragmatic modiﬁcations is
unknown, but intraperitoneal carboplatin is being evaluated in JGOG-
and NRG-sponsored clinical trials.
Bevacizumab 7.5–15 mg/kg every 3 weeks may be added to these
regimens [67,68]. Two studies have reported a modest, but statistically
signiﬁcant increase in progression-free survival in patients receiving
maintenance bevacizumab following carboplatin, paclitaxel, and
concurrent bevacizumab [67,68]. There is no evidence as yet to demon-
strate an overall survival beneﬁt, but a subgroup analysis of the Interna-
tional Collaboration on Ovarian Neoplasms 7 (ICON7) trial found that
there was an improved median survival (30.3 vs 39.4 months) in pa-
tients with suboptimal Stage III and Stage IV [67]. The role, optimal
dose, timing (primary vs recurrent disease), and duration of treatment
of bevacizumab are still controversial.
In patients who may not tolerate combination chemotherapy
because of medical comorbidities or advanced age, single-agent,
intravenously administered carboplatin (AUC 5–6) can be given.
In patients who have a signiﬁcant hypersensitivity reaction to pacli-
taxel, an alternative active drug can be substituted (e.g. docetaxel or
nanoparticle paclitaxel). Carboplatin hypersensitivity is very uncom-
mon in the ﬁrst-line setting, but is seen in some patients with recurrent
disease who have multiple lines of platinum-based chemotherapy.
In the case of carboplatin hypersensitivity, desensitization could be
attempted, depending on the severity of the reaction, or alternatively
cisplatin (50–75 mg/m2) may be an option but there still may be a
risk of a severe allergic reaction.
The treatment of all patients with advanced stage disease is
approached in a similar manner, with dose modiﬁcations based on the
toxicity of therapy. Care should be takenwhen considering combination
chemotherapy in patients with a very poor performance status or with
compromised renal function.7. Secondary surgery
7.1. Second-look laparotomy
A second-look laparotomy (or laparoscopy) was previously per-
formed in patients who have no clinical evidence of disease after com-
pletion of ﬁrst-line chemotherapy to determine response to treatment.
Although of prognostic value, it has not been shown to inﬂuence
survival, and is no longer recommended as part of the standard of care
[69]. Level of Evidence C7.2. Secondary cytoreduction
Secondary cytoreduction may be deﬁned as an attempt at cyto-
reductive surgery at some stage following completion of ﬁrst-line che-
motherapy. Retrospective studies suggest that patients beneﬁt if all
macroscopic disease can be removed, which usually means patients
with a solitary recurrence. Patients with a disease-free interval longer
than 12–24 months and those with only 1–2 sites of disease appear to
derivemost beneﬁt [70,71]. The role of secondary cytoreductive surgery
is being evaluated in randomized clinical trials. Level of Evidence C
8. Follow-up for malignant epithelial tumors
There is no evidence to show that intensive clinical monitoring dur-
ing follow-up after completion of primary surgery and chemotherapy
with early initiation of chemotherapy in asymptomatic womenwith re-
current disease improves overall survival or quality of life. In asymp-
tomatic patients with CA125 progression and small volume disease or
no radiological evidence of recurrence, it is appropriate to delay starting
chemotherapy. However, there may be a subset of patients who are
suitable for secondary debulking surgery at the time of recurrence.
The objectives of follow-up include:
• Assessment of response to the treatment.
• Early recognition and prompt management of treatment-related
complications, including provision of psychological support.
• Early detection of symptoms or signs of recurrent disease.
• Collection of data regarding the efﬁcacy of any treatment and the
complications associated with those treatments in patients treated
in clinical trials.
• Promotion of healthy behavior, including screening for breast cancer
in patients with early stage disease, and screening for cervical cancer
in patients having conservative surgery.
There are no evidence-based guidelines regarding the appro-
priate follow-up schedule. During the ﬁrst year following treatment,
patients are seen every 3 months with a gradual increase in intervals
to every 4–6 months after 2 years and then annually after the ﬁfth
year. At each follow-up, the patient should have her history retaken,
including any change in family history of cancers and attention to
any symptoms that could suggest recurrence; a physical and pelvic
examinationshould be performed. This is an opportunity to refer appro-
priate patients for genetic testing if it was not done at diagnosis or
during treatment. The CA125 has traditionally been checked at regular
intervals, but there has been debate regarding the clinical beneﬁt of
using CA125 progression alone as a trigger for initiating second-line
chemotherapy. A large MRC OV05-EORTC 55955 study showed that
treating asymptomatic patients with recurrent ovarian cancer with
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survival and early treatment in asymptomatic patients had a negative
impact on quality of life [72]. This study has generated considerable de-
bate regarding the use of CA125 for follow-up, but most agree that it is
reasonable not to immediately initiate treatment unless there is a clear
clinical indication to do so. The timing of treatment should be based on
symptoms as well as clinical and radiological ﬁndings. Imaging tests
such as ultrasonography of the pelvis, CT,MRI, and/or positron emission
tomography (PET) scans should be performed only when the clinical
ﬁndings or the tumor markers suggest possible recurrence.
There appears to be no beneﬁt to initiating chemotherapy in an
asymptomatic patient with recurrent disease based only on rising
CA125 levels in the absence of clinical symptoms or radiological evi-
dence of recurrence. In asymptomatic patients with small volume dis-
ease and no radiological evidence of recurrence, close observation is a
reasonable option, as well as entry into an appropriate clinical trial or
tamoxifen may be considered.
A Cochrane database systematic review of tamoxifen in unselected
women with recurrent ovarian cancer reported a 10% objective re-
sponse and a 32% disease stabilization rate [73]. The patients treated
were very heterogeneous and included asymptomatic patients with ris-
ing CA125 levels, and symptomatic patients with chemotherapy-
resistant disease who had been heavily pretreated and had a poor
performance status. GOG 198 compared tamoxifen and thalidomide in
women with recurrent FIGO Stage III or IV epithelial ovarian, tubal, or
peritoneal cancer who had completed ﬁrst-line chemotherapy, and
who subsequently had Gynecologic Cancer InterGroup (GCIG) docu-
mented CA125 progression. The study reported that women who re-
ceived thalidomide had a 31% increased risk of disease progression
(hazard ratio, 1.31), compared with those who were given tamoxifen
[74]. The median progression-free survival was 3.2 months in the tha-
lidomide group versus 4.5months in the tamoxifen group. This suggests
that tamoxifen may have a role in selected patients with a rising CA125
level, and the relationship between estrogen receptor positivity and
beneﬁt of tamoxifen in this patient population is being evaluated in
current studies.
9. Chemotherapy for recurrent epithelial malignancies
The majority of patients who present with advanced epithelial
cancers of the ovary/fallopian tube/peritoneumwill relapse with a me-
dian time to recurrence of 16 months. Patients with recurrent ovarian
cancer constitute a heterogeneous group with a variable prognosis,
and a variable response to further treatment. Themostwidely used clin-
ical surrogate for predicting response to subsequent chemotherapy and
prognosis has been the progression-free interval or the “platinum-free
interval,” which is deﬁned as the time from cessation of primary
platinum-based chemotherapy to disease recurrence or progression
[75,76]. This has been useful to deﬁne speciﬁc patient populations, but
it has a number of limitations and depends on how patients are follow-
ed. In particular, it depends on how recurrence is detected and deﬁned.
Patients with a treatment-free interval of less than 6 months are classi-
ﬁed as platinum resistant and generally treated with nonplatinum-
based chemotherapy, while those with a treatment-free interval of
more than 6 months are considered to be platinum sensitive and com-
monly treated with platinum-based chemotherapy. Patients who prog-
ress while on treatment or within 4 weeks of stopping chemotherapy
are classiﬁed as platinum refractory [75,76].
There have been modiﬁcations to these deﬁnitions, and time to
progression or recurrence rather than treatment-free interval or
platinum-free interval has been used to deﬁne speciﬁc patient popula-
tions. There has been signiﬁcant change in practice over the last
20 years and patients have been routinely followed with regular
CA125 testing after completion of chemotherapy. For example, the
“platinum-resistant” subgroup may include asymptomatic patients
with CA125 progression alone at 3 months post chemotherapy orradiological evidence of recurrence as well as those who are symptom-
atic with clinical recurrence. The 4th Ovarian Cancer Consensus
Conference reached agreement that distinct patient populations should
be based on the interval from last platinum therapy and the time to
progression. The progression-free interval is deﬁned from the last date
of platinum dose until progressive disease is documented [75,76].
For patients whose disease is considered platinum-sensitive, the
ICON 4 study showed advantage in terms of overall survival and
progression-free survival for a combination of carboplatin and paclitaxel
versus single-agent carboplatin [77]. Level of Evidence A
For patients with neurotoxicity, gemcitabine [78] or liposomal
doxorubicin [79] may be substituted for the paclitaxel. Level of
Evidence A
There is evidence that the addition of bevacizumab to the regimen of
carboplatin and gemcitabine improves progression-free survival
compared with carboplatin and gemcitabine in platinum-sensitive
disease [80].
For patients with deﬁnite platinum-resistant disease, enrollment on
available clinical trials or treatment with nonplatinum chemotherapy
should be considered. There are a number of chemotherapy options
including liposomal doxorubicin [81], topotecan [81], etoposide [82,
83], and gemcitabine [84,85]. The reported response rates are low,
about 10%, with a median time to progression of 3–4 months and a
median survival of 9–12 months. Over the last 5 years there have been
a number of trials carried out with new agents in patients with
platinum-resistant ovarian cancer, including epothilones, trabectedin
[86] and permetrexed [87] with no signiﬁcant increase in response
rates or progression-free survival. No new cytotoxic agent has been
approved to treat recurrent ovarian cancer for many years. The role
of angiogenesis inhibitors in platinum-resistant ovarian cancer is
discussed below.
The optimalmanagement of a patientwith platinum-resistant or re-
fractory disease is complex and requires a careful assessment of the pa-
tient’s performance status, symptoms, and extent of disease. Attention
to symptom control and good palliative care is an essential component
of management.
With very few exceptions, recurrent disease is not curable and
the aim of treatment is to maintain quality of life and palliate symp-
toms particularly in patients with platinum resistant ovarian can-
cer [88]. There are many potential treatment options, including
chemotherapy, angiogenesis inhibitors, radiation therapy, or surgery
in selected patients and inclusion in clinical trials [71]. There is a subset
of patients who may beneﬁt from secondary surgical debulking,
but they constitute a minority. The role of secondary surgical debulking
is being addressed in prospective randomized clinical trials. Level of
Evidence C
An extensive review of targeted therapies can be found in the
chemotherapy chapter included in the FIGO Cancer Report 2015 (this
Supplement) [89].
10. Management of epithelial tumors of low malignant potential
(borderline tumors)
Compared with invasive epithelial cancers, borderline tumors tend
to affect a younger population and constitute 15% of all epithelial tumors
of the ovary [90]. Nearly 75% of these are Stage I at the time of diagnosis.
The following can be said for these tumors [91]:
• The diagnosis must be based on the pathology of the primary tumor.
• Extensive sectioning of the tumor is necessary to rule out inva-
sive cancer.
• The prognosis of these tumors is extremely good, with a 10-year sur-
vival of about 95%.
• Invasive cancers that arise in borderline tumors are often indolent and
generally have a low response to platinum-based chemotherapy.
• Spontaneous regression of peritoneal implants has been observed.
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ated with a more favorable prognosis.
• Although gross residual disease after primary laparotomy is associat-
ed with poorer prognosis, mortality from the disease remains low.
• Those patients who have invasive implants in the omentum or other
distant sites are more likely to recur earlier, and although they are
commonly treated with cytotoxic chemotherapy the response rates
are low.
The causes of death include complications of disease (e.g. small
bowel obstruction) or complications of therapy, and only rarely malig-
nant transformation. The mainstay of treatment is primary surgical
staging and cytoreduction. For patients with Stage I disease who want
to preserve fertility, conservative surgery with unilateral salpingo-
oophorectomy can be considered after intraoperative inspection of
the contralateral ovary to exclude involvement [92]. For patients with
only one ovary, or bilateral cystic ovaries, a partial oophorectomy or
cystectomy can be considered for fertility preservation. For all other pa-
tients, total hysterectomy and bilateral salpingo-oophorectomy are rec-
ommended, with maximal cytoreduction if the disease is metastatic.
Patients with borderline tumors in all stages of disease should
be treated with surgery. A small percentage of patients with invasive
implants may beneﬁt from chemotherapy but the response to chemo-
therapy is unpredictable and generally much lower than that observed
in high-grade serous cancers. Uncommonly, some patients recur
early and have higher-grade invasive cancers and may beneﬁt from
chemotherapy [93].
In patients with late recurrence of the disease, secondary cyto-
reduction should be considered, and chemotherapy given only if inva-
sive disease is present histologically.
Follow-up of patients with no evidence of disease is the same as for
those with malignant epithelial carcinomas, but at less frequent inter-
vals. If the contralateral ovary has been retained, it should be followed
by transvaginal ultrasonography, at least on an annual basis [1,91,94].
Level of Evidence C
11. Management of granulosa cell tumors
Granulosa cell tumors account for about 70% of sex-cord stromal tu-
mors and 3%–5% of all ovarian neoplasms [2]. There are two types of
granulosa cell tumors: the juvenile and the adult types. Because of the
high estrogen production, the juvenile type typically presents with sex-
ual precocity, while the adult type may present with postmenopausal
bleeding. The majority of patients are diagnosed with Stage I tumors.
The peak incidence is in the ﬁrst postmenopausal decade [2,95].
Granulosa cell tumors are generally indolent (i.e. with a tendency to
late recurrence). Stage at diagnosis is the most important prognostic
factor. Other prognostic factors include age at diagnosis, tumor size,
and histological features. If metastatic, adequate cytoreduction is the
mainstay of treatment. If thepatient is young and the disease is conﬁned
to one ovary, conservative surgery should be performed [96,97].
The infrequency of the disease, and its protracted course, has result-
ed in a lack of prospective studies. There is no evidence that adjuvant
chemotherapy or radiotherapy improves the results of surgery alone
for Stage I disease. The value of postoperative adjuvant chemotherapy
for higher-risk Stage I disease (tumor size N10 cm, capsule rupture,
highmitotic count) is uncertain, and has not been tested in randomized
studies. Platinum-based chemotherapy is used for patients with
advanced or recurrent disease, with an overall response rate of 63%–
80% [97–99].
Follow-up is clinical. For patients with elevated levels of inhibin B
and/or AMH at initial diagnosis of granulosa cell tumors, inhibin B and/
or AMH appear to be reliable markers during follow-up for early detec-
tion of residual or recurrent disease. There is no evidence-based prefer-
ence for inhibin B or AMH as a tumor marker [100]. Serum inhibin is a
useful tumor marker in postmenopausal women. Level of Evidence C12. Management of germ cell malignancies
This group of ovarian tumors consists of a variety of histologically
different subtypes that are all derived from the primitive germ cells of
the embryonic gonad.Malignant germ cell tumors represent a relatively
small proportion of all ovarian tumors. Prior to advances in chemother-
apy, the prognosis for these aggressive tumors was poor. The use of
platinum-based chemotherapeutic regimes has made germ cell malig-
nancies among the most highly curable cancers [95].
12.1. Presentation
The highest incidence of malignant germ cell tumors occurs in the
second and third decades of life. They are frequently diagnosed by ﬁnd-
ing a palpable abdominalmass in a youngwomanwho complains of ab-
dominal pain. The following are the symptoms of germ cell tumors in
order of frequency [95]:
• Acute abdominal pain.
• Chronic abdominal pain.
• Asymptomatic abdominal mass.
• Abnormal vaginal bleeding.
• Abdominal distention.
12.2. Histological classiﬁcation
The classiﬁcation of germ cell tumors of the ovary is important to
determine prognosis and for treatment with chemotherapy. Germ cell
tumors are classiﬁed as follows [2,95]:
• Dysgerminoma.
• Embryonal carcinoma.
• Polyembryoma.
• Teratoma (immature; mature; mature with carcinoma [squamous
cell, carcinoid, neuroectodermal, malignant struma, etc.]).
• Extraembryonal differentiation (choriocarcinoma; endodermal sinus
tumor [yolk sac tumor]).
12.3. Diagnosis, staging, and surgical management
Ovarian germ cell tumors are staged similarly to epithelial carcino-
mas, although the staging system used for male germ cell tumors is
probablymore useful. The approach to treatment is based on the princi-
ples ofmanagement ofmetastatic germ cell tumors of the testis (i.e. low,
intermediate, and poor risk). Dysgerminoma is the equivalent of
seminoma in testicular cancer [101]. It is exquisitely sensitive to
platinum-based chemotherapy and is radiosensitive. The cure rate is
high irrespective of the stage. The other histological subtypes are equiv-
alent to nonseminomatous testicular cancer. The aggressiveness of the
disease is dependent on the type, the most aggressive being endoder-
mal sinus and choriocarcinoma, but with combination chemotherapy,
they are highly curable [102–106].
As chemotherapy can cure the majority of patients, even with ad-
vanced disease, conservative surgery is standard in all stages of all
germ cell tumors. Conservative surgery means laparotomy with careful
examination and biopsy of all suspicious areas, with limited cytore-
duction, thereby avoiding major morbidity. The uterus and the contra-
lateral ovary should be left intact. Wedge biopsy of a normal ovary is
not recommended as it defeats the purpose of conservative therapy by
potentially causing infertility. Patientswho receive conservative surgery
with the preservation of one ovary retain acceptable fertility rates de-
spite adjuvant treatment with chemotherapy. There has been no report
of higher adverse obstetric outcome or long-term unfavorable sequelae
in the offspring [107–110].
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whose tumor was not completely resected at the initial operation and
who had teratomatous elements in their primary tumor. Surgical resec-
tion of residual masses may be beneﬁcial in such patients, as there
may be mature teratomatous nodules that can continue to increase in
size [111].
12.4. Postoperative management and follow-up of dysgerminoma
Patientswith Stage IA diseasemay be observed after surgery. A small
proportion of patients may recur, but they can be treated successfully at
the time of recurrencewith a high rate of cure. Patients with disease be-
yond the ovary should receive adjuvant chemotherapy. Although radia-
tion therapy is effective, ovarian failuremakes it undesirable for patients
with an intact ovary. The long-term adverse effects are greater than
with chemotherapy and radiotherapy is now rarely used.
A follow-up surveillance regime for patients with Stage 1A
dysgerminoma is outlined in Table 4. This schedule is based on the ex-
perience managing seminomas in males and the reports by Patterson
et al. [112] and Dark et al. [113]. This pragmatic follow-up schedule
and has not been tested in randomized trials.
12.4.1. Chemotherapy for dysgerminoma
Dysgerminoma is extremely sensitive to chemotherapy, and treat-
ment with chemotherapy cures the majority of patients, even with ad-
vanced disease [95,114]. The recommended chemotherapy regimen is
as follows:
• Etoposide (E) 100 mg/m2 IV per day for 5 days every 3 weeks for
3 cycles.
• Cisplatin (P) 20 mg/m2 IV per day for 5 days every 3 weeks for
3 cycles.
• Bleomycin (B) 30 000 IU IV/IM ondays 1/8/15 for 12weeks (Optional)
(Note: bleomycin is dosed in International Units). If bleomycin is
omitted, then 4 cycles of EP are commonly used. Note that various
schedules of bleomycin have been used.
When there is bulky residual disease, it is common to give 3–4
courses of BEP chemotherapy [114]. Level of Evidence BTable 4
Follow-up regime for Stage I germ cell malignancies.a
Regimen Description
Surveillance Baseline CT chest, abdomen, and pelvis, if not
performed preoperatively
Repeat CT or MRI, abdomen and pelvis at 3 months
after surgery
Repeat CT or MRI abdomen plus pelvis at 12 months
Pelvic ultrasound alternate visits (not when having
CT scan) for 2 years if non-dysgerminoma and for
3 years if dysgerminoma
Chest X-ray at alternate visits
Clinical examination
1 year Monthly
2nd year 2 monthly
3rd year 3 monthly
4th year 4 monthly
Years 5–10 6 monthly
Tumor marker follow-up Samples: serum AFP and hCG, LDH and CA 125
(regardless of initial value)
0–6 months 2 weekly
7–12 months 4 weekly
12–24 months 8 weekly
24–36 months 12 weekly
36–48 months 16 weekly
48+ months 6 monthly until year 10
Abbreviations: AFP, alpha-fetoprotein; hCG, human chorionic gonadotropin; LDH, lactate
dehydrogenase.
a Adapted from Patterson et al. [112].The optimal follow-up schedule has not been clinically investigated
in ovarian germ cancers and the frequency of visits and investigations is
controversial. Patients who have Stage I tumors and who are offered
surveillance need to be seen regularly and one option is to utilize the
follow-up regimen presented above [113]. Patients who have had che-
motherapy have a lower risk of recurrence and the frequency of CT
scans can be reduced, which is similar to the approach for testicular
germ cell tumors [112]. Each follow-up visit should involve taking a
medical history, physical examination, and tumor marker determina-
tion. Although tumor markers are important, radiological imaging is
also pertinent, especially for patients whose tumor markers were not
raised at diagnosis. CT or MRI scans should be performed as clinically
indicated [113].
Patients who have not received chemotherapy should be followed
closely. Ninety percent of relapses in these patients occur within the
ﬁrst 2 years. At relapse, with few exceptions, these patients can be
successfully treated [113]. Level of Evidence D
12.5. Postoperative management and follow-up of non-dysgerminoma
germ cell malignancies
These tumors are highly curable with chemotherapy, even with ad-
vanced disease. Patients with Stage IA grade 1–2 immature teratoma
have a very good prognosis and should be only observed after primary
conservative surgery. It is controversial whether adjuvant chemothera-
py adds any survival beneﬁt in this subgroup of patients. All other
patients with non-dysgerminomas, and higher-stage and higher-grade
immature teratomas should receive postoperative adjuvant chemother-
apy [95].
The recommended chemotherapy regimen is etoposide 100 mg/m2
per day for 5 days with cisplatin 20 mg/m2 per day for 5 days, and
bleomycin at 30 000 IU IM/IV on days 1, 8, and 15 for a total of
12 weeks of treatment. For patients with good prognosis disease,
3 cycles of BEP are recommended, while patients with intermediate/
poor risk disease should receive 4 cycles of BEP [95].
Patients who relapse after BEP may still attain a durable remis-
sion with secondary chemotherapy regimens such as paclitaxel–
ifosfamide–cisplatin (TIP) [104]. High-dose chemotherapy and autolo-
gous marrow rescue may be considered in selected patients. These
patients should be managed in specialized units.
After chemotherapy, patients with metastatic immature teratomas
can sometimes have residual masses, which are composed entirely of
mature elements. These masses can grow, and should be resected
after the completion of chemotherapy. Level of Evidence B
All patients should have lactate dehydrogenase (LDH), alpha-
fetoprotein (AFP), and human gonadotropin (beta hCG) blood tests
performed to monitor response to treatment. All patients treated with
chemotherapy should be followed-up with medical history, physical
examination, and appropriate tumor markers in the same way as
dysgerminomas. CT or MRI scans should be performed as clinically
indicated [93].
Relapses in patients usually occur within the ﬁrst 2 years after
diagnosis [95,104] Level of Evidence D
13. Sarcoma of the ovary
Ovarian sarcomas are rare and occur primarily in postmenopausal
patients [95,115]. Nevertheless, accurate diagnosis and differentiation
from other types of primary ovarian cancer are important, as the prog-
nosis is generally poor.
There are two types of sarcoma. Malignant mixed Müllerian tumors
(MMMTs), themore commonof the two, are biphasic tumors composed
of both carcinomatous and sarcomatous elements [115,116]. Most au-
thors agree that most MMMTs are monoclonal in origin and should be
thought of andmanaged as a high-grade epithelial cancer. The sarcoma-
tous component is derived from the carcinoma or from a stem cell that
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best regarded as metaplastic carcinomas.
Pure sarcomas are very rare and should be treated according to the
speciﬁc histological subtype. These rare sarcomas include ﬁbrosar-
comas, leiomyosarcomas, neuroﬁbrosarcomas, rhabdomyosarcomas,
chondrosarcomas, angiosarcomas, and liposarcomas. Their manage-
ment is not discussed here.
Patients with early stage MMMTs have a better outcome than those
with advanced stage disease, but the overall prognosis is poor. They
should be managed similarly to high-grade pelvic serous cancers.
Their rarity prohibits any prospective randomized trials.
The principles of surgical management of ovarian MMMTS are the
same as for high-grade pelvic serous cancers [95]. Following surgery,
patients should receive platinum-based chemotherapy [95,113,114].
The follow-up schedule is as recommended for epithelial malignancies.
Level of Evidence C
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